Gilles Montalescot, Head of Cardiac Care Unit at Pitie-Salpetriere Hospital in Paris and lead investigator of the ATOLL study. ‘By enabling maintenance of the same anticoagulant throughout individual management from the emergency room or the ambulance to the catheterization laboratory after that to the Cardiac Care Unit, without anticoagulation monitoring, enoxaparin can be securing and simplifying the treatment technique’ he added. The international ATOLL research sponsored by the Assistance Publique – Hopitaux de Paris enrolled 910 patients suffering from ST-elevated Myocardial Infraction , the most unfortunate form of heart attack.The most typical adverse event was injection site reactions which were predominantly slight and typically resolved within days. There were ‘no flu-like’ symptoms, no abnormalities in renal function, no clinically meaningful adjustments in other laboratory ideals reported as adverse occasions. Liver enzyme elevations were noted as adverse events in two patients but aren’t being regarded as clinically meaningful in these situations. The positive basic safety profile demonstrated to time suggests the drug could be tolerated at higher dosage levels than 400 mg weekly. Preparation for Stage III Advancement As previously reported, THE BUSINESS plans to conduct a little study at an increased dose than 400 mg per week for potential make use of in a Phase III medical trial. Preparatory function for a Stage III clinical trial of 6 -12 weeks of treatment includes manufacture and formulation of medication product and additional animal toxicology studies which ANP programs to undertake with a future development partner.
AMN Healthcare launches brand-new corporate brand identity In order to more effectively symbolize its position as the leader in the healthcare staffing and administration services industry and the initial strength of its interconnecting service offerings, AMN Healthcare announced today that it has launched a fresh corporate brand identity.